Jeff Cislini Sells 1,500 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini sold 1,500 shares of the firm’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $30.99, for a total value of $46,485.00. Following the transaction, the general counsel now owns 54,374 shares in the company, valued at $1,685,050.26. The sale was disclosed in a document filed with the SEC, which is available at this link.

Jeff Cislini also recently made the following trade(s):

• On Monday, March 18th, Jeff Cislini sold 1,252 shares of Revolution Medicines stock. The shares were sold at an average price of $31.58, for a total value of $39,538.16.
• On Monday, January 22nd, Jeff Cislini sold 1,500 shares of Revolution Medicines stock. The shares were sold at an average price of $27.00, for a total value of $40,500.00.

Revolution Medicines Stock Performance

Shares of RVMD opened at $32.23 on Friday. The business has a 50-day moving average of $30.02 and a 200 day moving average of $27.19. Revolution Medicines, Inc. has a fifty-two week low of $15.44 and a fifty-two week high of $35.60. The firm has a market cap of $5.31 billion, a P/E ratio of -8.55 and a beta of 1.53.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Monday, February 26th. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.29). The company had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $1.20 million. Revolution Medicines had a negative net margin of 1,003.36% and a negative return on equity of 38.39%. The firm’s quarterly revenue was down 95.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.63) EPS. As a group, research analysts predict that Revolution Medicines, Inc. will post -3.17 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RVMD has been the subject of several research analyst reports. UBS Group initiated coverage on Revolution Medicines in a research report on Wednesday, December 20th. They set a “buy” rating and a $40.00 target price for the company. Wedbush raised their target price on Revolution Medicines from $41.00 to $42.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. Raymond James raised their target price on Revolution Medicines from $30.00 to $36.00 and gave the company an “outperform” rating in a research report on Tuesday, January 16th. Bank of America raised Revolution Medicines from a “neutral” rating to a “buy” rating and raised their target price for the company from $31.00 to $34.00 in a research report on Friday, January 5th. Finally, Piper Sandler initiated coverage on Revolution Medicines in a research report on Monday, March 11th. They set an “overweight” rating and a $43.00 target price for the company. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Revolution Medicines currently has an average rating of “Buy” and an average target price of $38.80.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in RVMD. Point72 Hong Kong Ltd purchased a new position in Revolution Medicines during the 2nd quarter valued at about $39,000. US Bancorp DE grew its holdings in Revolution Medicines by 68.1% during the 2nd quarter. US Bancorp DE now owns 1,575 shares of the company’s stock valued at $42,000 after buying an additional 638 shares in the last quarter. Shell Asset Management Co. purchased a new position in Revolution Medicines during the 4th quarter valued at about $54,000. KBC Group NV purchased a new position in Revolution Medicines during the 4th quarter valued at about $65,000. Finally, Tower Research Capital LLC TRC grew its holdings in Revolution Medicines by 76.5% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,418 shares of the company’s stock valued at $74,000 after buying an additional 1,481 shares in the last quarter. Hedge funds and other institutional investors own 94.34% of the company’s stock.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.